In Setback For Mylan, Judge Upholds Levaquin Patent

Law360, New York (January 2, 2005, 12:00 AM EST) -- A federal judge has barred Mylan Laboratories Inc. from making a generic version of the antibiotic Levaquin until at least December 2010.

Last week, U.S. District Judge Irene M. Keeley prohibited Mylan from making or selling levofloxacin tablets, a generic form of Levaquin.

The drug is used to treat a variety of conditions, including bronchitis, sinusitis and urinary tract infections.

Ortho-McNeil Pharmaceutical Inc., a Johnson & Johnson company that sells Levaquin in the U.S., and Japanese patent-owner Daiichi Pharmaceutical Co. had filed their first lawsuit in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.